Startups

    Ellipses Pharma lines up a London listing at up to £500m via a reverse takeover, with Mubadala holding 45%

    Ellipses Pharma, the clinical-stage cancer drug developer founded by Sir Chris Evans, is preparing to list in London at a valuation of £450m to £500m by reversing into the cash shell Wolfram Resources. Abu Dhabi sovereign wealth fund Mubadala is its largest shareholder with a 45% stake.

    T

    The Cap Table

    17 November 20263 min read
    Ellipses Pharma lines up a London listing at up to £500m via a reverse takeover, with Mubadala holding 45%

    Ellipses Pharma, the clinical-stage cancer drug developer founded by Sir Chris Evans, is preparing to list in London at a valuation of £450m to £500m by reversing into the cash shell Wolfram Resources. Abu Dhabi sovereign wealth fund Mubadala is its largest shareholder with a 45% stake.

    Ellipses is a London-based oncology company that licenses and develops cancer drugs through clinical trials. It employs about 40 people, most of them drawn from large pharmaceutical groups, and has invested roughly £185m in its drug pipeline, according to a report by The Times, followed up by City AM on 16 November.

    The deal structure

    Rather than a traditional initial public offering, Ellipses plans to come to market through a reverse takeover of Wolfram Resources, a listed shell previously focused on precious metals exploration in central Asia. The transaction could complete as soon as February.

    Private bank Berenberg has reportedly been appointed to manage the deal. Ellipses is also preparing to add non-executive directors to its board before listing. Royal Bank of Canada and M&A adviser Pharma Ventures are understood to have been lined up to advise on potential out-licensing deals with large drugmakers. A formal announcement could come this week.

    Reverse takeovers give private companies a faster route to public-market capital than an IPO, and have become more common on Nasdaq this year.

    Who owns Ellipses

    The cap table is unusual for a UK biotech. Mubadala Investment Company holds 45%, making it the single largest investor. Waleed al-Mokarrab al-Muhairi, Mubadala's deputy chief executive, sat on the Ellipses board until March 2025. The company started a clinical trial programme in the UAE in December 2024.

    The remaining shareholders include Evans himself, Redrow founder Steve Morgan and West Coast Capital, the investment vehicle of Scottish entrepreneur Sir Tom Hunter. Comedian Jimmy Carr and composer Andrew Lloyd Webber are also investors. The size of their individual holdings was not disclosed.

    At the top of the target range, Mubadala's 45% would be worth about £225m on listing.

    Why London, and why now

    Evans, whose earlier ventures include Enzymatix and Celsis, had considered Nasdaq for Ellipses, and Hong Kong was floated as an option in 2025. Choosing London would give the market a rare life sciences listing at a time when delistings and IPOs moving overseas have weighed on the exchange, and when larger groups such as AstraZeneca have moved closer to US capital markets.

    The terms of any capital raise alongside the reverse takeover, including how much new money Ellipses will seek and how much existing holders will be diluted, have not been disclosed. Those figures, along with the composition of the new board, will be the key details to watch when a formal announcement is made.


    Original source: City AM — https://www.cityam.com/celebrity-backed-cancer-treatment-venture-eyes-london-listing/

    T

    Written by

    The Cap Table

    Stay in the loop

    Get the biggest stories from the UK startup ecosystem straight to your inbox. No spam, just what matters.

    Related stories